Literature DB >> 11337104

Imidazo[1,2-a]quinoxalines: synthesis and cyclic nucleotide phosphodiesterase inhibitory activity.

S Parra1, F Laurent, G Subra, C Deleuze-Masquefa, V Benezech, J Fabreguettes, J Vidal, T Pocock, K Elliott, R Small, R Escale, A Michel, J Chapat, P Bonnet.   

Abstract

A group of imidazo[1,2-a]quinoxalines have been synthesised from quinoxaline by condensation of an appropriate haloester or intramolecular cyclisation of a keto moiety on an intracyclic nitrogen atom. The reactivity of the heterocycle was explored through diverse reactions such as electrophilic substitution, lithiation and halogen-metal exchange to give access to a new series of derivatives. Confirmation of their structure was mainly performed by NMR, after careful assignment of the signals in comparison to previous attributions made on the parent imidazo[1,2-a]quinoxaline and discussion of available data in the literature. The cyclic nucleotide phosphodiesterase inhibitor activity of some of these derivatives has been assessed on isoenzymes type III and type lV. Compound 15, 4-(methylamino)imidazo[1,2-a]quinoxaline-2-carbonitrile, exhibited potent relaxant activity on smooth muscle, with a potency similar to the one measured with SCA 40, its structural analogue in the imidazo[1,2-a]pyrazine series.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11337104     DOI: 10.1016/s0223-5234(01)01213-2

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  2 in total

1.  Computational discovery of novel inhibitory candidates targeting versatile transcriptional repressor MBD2.

Authors:  Zihni Onur Çalışkaner
Journal:  J Mol Model       Date:  2022-09-06       Impact factor: 2.172

2.  Sensing study of quinoxaline analogues with theoretical calculation, single-crystal X-ray structure and real application in commercial fruit juices.

Authors:  Shampa Chakraborty; Shyamaprosad Goswami; Ching Kheng Quah; Bholanath Pakhira
Journal:  R Soc Open Sci       Date:  2018-06-06       Impact factor: 2.963

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.